Efficacy and Safety of Janus Kinase (JAK1) Selective Inhibitors in the Treatment of Atopic Dermatitis: A Systematic Review and Meta-Analysis
Published: 16 April 2024| Version 1 | DOI: 10.17632/742wzhgpwz.1
Contributors:
Mingyue Wang, Xing-Hua Gao, Li ZhangDescription
The "Efficacy and Safety of Janus Kinase (JAK1) Selective Inhibitors in the Treatment of Atopic Dermatitis: A Systematic Review and Meta-Analysis" publication uses these data as supplemental information. JAK1-selective inhibitors are widely used as small-molecule targeted agents for the treatment of patients with atopic dermatitis, in this study, we found that JAK1-selective inhibitor monotherapy was more efficacious than the combination, but the incidence of treatment-related adverse effects was subsequently elevated. More data are needed to investigate the efficacy and safety of selective JAK1 inhibitors in the future.
Files
Categories
Dermatology, Atopic Dermatitis, Janus Kinase